ArticleTranslational cancer research2020
Clinicopathological characteristics and treatment outcomes of cutaneous extranodal natural killer/T-cell lymphoma: a retrospective study in China.
Article in Translational cancer research, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed, 2 citations in OpenAlex.
- Low absolute CD4Annals of translational medicine · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundExtranodal natural killer/T-cell lymphoma (ENKTL) is a special subtype of non-Hodgkin lymphoma that is subcategorized into ENKTL-nasal and ENKTL-nasal type. Cases with extranasal involvement show an aggressive clinical course with poor prognosis and low survival rates. The skin is the second most commonly affected organ, and such cases are defined as cutaneous ENKTL. However, there is limited information on the clinicopathologic features and prognostic factors of cutaneous ENKTL.
methodsWe reviewed the pathologic, immunohistochemical, and clinical data for 47 cases of cutaneous ENKTL.
resultsCutaneous ENKTL mainly involved the torso and extremities, with lesions presenting as single or multiple nodules, erythema and rash, or painless necrotic ulcers. There was high surface CD3 expression. The median survival time was 4.0 months (95% CI: 2.3-5.7 months). Stage I/II patients had a better outcome, with a mean survival time of >26 months (95% CI: 17.68-35.92 months). Stage III/IV patients had very poor outcome, with overall survival of 4.7 months (95% CI: 1.01-2.73 months). The presence of B symptoms, advanced tumor stage, increased lactate dehydrogenase level, high International Prognostic Index (IPI), and abnormal hemoglobin were independent prognostic factors for poor survival. Patients were more responsive to treatment with an L-asparaginase-based chemotherapy regimen than to other therapeutic approaches.
conclusionsCutaneous and primary nasal ENKTL differ in terms of clinical and biological characteristics. Cutaneous ENKTL has a short median survival time. Although an L-asparaginase-containing chemotherapy regimen was effective, a standardized treatment strategy remains to be established for cutaneous ENKTL.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.